A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3)

Trial Profile

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Everolimus; Imatinib; Infliximab; Methotrexate; Mycophenolate mofetil; Pentostatin; Sirolimus
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH3
  • Sponsors Incyte Corporation; Novartis; Novartis Pharma A.G.
  • Most Recent Events

    • 23 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 07 Apr 2017 Status changed from planning to not yet recruiting.
    • 16 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top